» Articles » PMID: 27436155

Trends in the Diagnosis and Clinical Features of Melanoma in Situ (MIS) in US Men and Women: A Prospective, Observational Study

Overview
Specialty Dermatology
Date 2016 Jul 21
PMID 27436155
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The incidence of melanoma in situ (MIS) is increasing, but little is known about its clinical and epidemiologic features.

Objective: We sought to determine trends in diagnosis and clinical features of MIS.

Methods: Incident cases of melanoma were collected prospectively from the Nurses' Health Study (1976-2010) and Health Professionals Follow-up Study (1986-2010).

Results: MIS incidence increased from 2 to 42 per 100,000 person-year among women, and from 11 to 73 per 100,000 person-year among men, exceeding the rate of increase of invasive melanomas. Melanoma mortality initially increased during the follow-up period then plateaued. Men were more likely than women to develop in situ melanomas on the upper half of the body (P < .001). Invasive melanomas were diagnosed at a younger age than MIS (P < .001), and were more likely to be found on the lower extremities than MIS (P < .001).

Limitations: This is a strictly descriptive study without examination into mechanisms.

Conclusion: We found epidemiologic and clinical differences for in situ and invasive melanomas, which support further examination into the variations in etiologic pathways. The lack of improvement in mortality despite the increase in detection of in situ relative to invasive lesions further highlights the need to improve invasive melanoma-specific clinical screening features.

Citing Articles

Integrated transcriptomic and immunological profiling reveals new diagnostic and prognostic models for cutaneous melanoma.

Li C, Wu N, Lin X, Zhou Q, Xu M Front Pharmacol. 2024; 15:1389550.

PMID: 38863979 PMC: 11165152. DOI: 10.3389/fphar.2024.1389550.


Survival in patients diagnosed with melanoma in situ compared to the general population. A Swedish population-based matched cohort study.

Naeser Y, Mikiver R, Ingvar C, Lambe M, Ullenhag G EClinicalMedicine. 2023; 65:102284.

PMID: 38106551 PMC: 10725068. DOI: 10.1016/j.eclinm.2023.102284.


Topical and Intralesional Immunotherapy for Melanoma In Situ: A Review.

Martinez-Fernandez S, Gonzalez-Sixto B, Espasandin-Arias M, Soto-Garcia D, Florez A Cancers (Basel). 2023; 15(18).

PMID: 37760438 PMC: 10526313. DOI: 10.3390/cancers15184468.


The risk of subsequent invasive melanoma after a primary in situ or invasive melanoma in a high incidence country (New Zealand).

Win Myint T, Selak V, Elwood M Skin Health Dis. 2023; 3(2):e116.

PMID: 37013115 PMC: 10066759. DOI: 10.1002/ski2.116.


Demographic, Clinical, and Pathologic Features of Patients With Cutaneous Melanoma: Final Analysis of the Brazilian Melanoma Group Database.

Wainstein A, Duprat Neto J, Enokihara M, Brechtbuhl E, Riccardi F, Landman G JCO Glob Oncol. 2020; 6:575-582.

PMID: 32293941 PMC: 7193775. DOI: 10.1200/JGO.20.00005.


References
1.
Tejera-Vaquerizo A, Mendiola-Fernandez M, Fernandez-Orland A, Herrera-Ceballos E . Thick melanoma: the problem continues. J Eur Acad Dermatol Venereol. 2007; 22(5):575-9. DOI: 10.1111/j.1468-3083.2007.02517.x. View

2.
To T, Wall C, Baines C, Miller A . Is carcinoma in situ a precursor lesion of invasive breast cancer?. Int J Cancer. 2014; 135(7):1646-52. DOI: 10.1002/ijc.28803. View

3.
Clegg L, Feuer E, Midthune D, Fay M, Hankey B . Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002; 94(20):1537-45. DOI: 10.1093/jnci/94.20.1537. View

4.
Pion I, Rigel D, GARFINKEL L, Silverman M, Kopf A . Occupation and the risk of malignant melanoma. Cancer. 1995; 75(2 Suppl):637-44. DOI: 10.1002/1097-0142(19950115)75:2+<637::aid-cncr2820751404>3.0.co;2-#. View

5.
Cho E, Rosner B, Colditz G . Risk factors for melanoma by body site. Cancer Epidemiol Biomarkers Prev. 2005; 14(5):1241-4. DOI: 10.1158/1055-9965.EPI-04-0632. View